We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?
Read MoreHide Full Article
BridgeBio Pharma (BBIO - Free Report) shares soared 15.1% in the last trading session to close at $90.17. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 16.2% gain over the past four weeks.
The upside came after rival AstraZeneca announced its phase III CARDIO-TTRansform study evaluating Wainua in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) failed to meet its primary endpoint. Investors viewed the setback as a favorable development for BridgeBio’s sole marketed drug, Attruby, as it could strengthen the drug’s competitive position in the ATTR-CM space by removing a potential rival.
This rare disease drug developer is expected to post quarterly loss of $0.64 per share in its upcoming report, which represents a year-over-year change of +32.6%. Revenues are expected to be $221.28 million, up 100.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For BridgeBio Pharma, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on BBIO going forward to see if this recent jump can turn into more strength down the road.
BridgeBio Pharma belongs to the Zacks Medical - Generic Drugs industry. Another stock from the same industry, Amphastar Pharmaceuticals (AMPH - Free Report) , closed the last trading session 0.7% higher at $19.02. Over the past month, AMPH has returned -7%.
For Amphastar, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.68. This represents a change of -20% from what the company reported a year ago. Amphastar currently has a Zacks Rank of #5 (Strong Sell).
View the Zacks #1 Rank List
Image: Bigstock
BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?
BridgeBio Pharma (BBIO - Free Report) shares soared 15.1% in the last trading session to close at $90.17. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 16.2% gain over the past four weeks.
The upside came after rival AstraZeneca announced its phase III CARDIO-TTRansform study evaluating Wainua in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) failed to meet its primary endpoint. Investors viewed the setback as a favorable development for BridgeBio’s sole marketed drug, Attruby, as it could strengthen the drug’s competitive position in the ATTR-CM space by removing a potential rival.
This rare disease drug developer is expected to post quarterly loss of $0.64 per share in its upcoming report, which represents a year-over-year change of +32.6%. Revenues are expected to be $221.28 million, up 100.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For BridgeBio Pharma, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on BBIO going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
BridgeBio Pharma belongs to the Zacks Medical - Generic Drugs industry. Another stock from the same industry, Amphastar Pharmaceuticals (AMPH - Free Report) , closed the last trading session 0.7% higher at $19.02. Over the past month, AMPH has returned -7%.
For Amphastar, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.68. This represents a change of -20% from what the company reported a year ago. Amphastar currently has a Zacks Rank of #5 (Strong Sell).